Publications by authors named "Elena Bermejo Marcos"
Prospective study about the security and efficacy of treatment without antibiotic therapy of patients diagnosed with acute uncomplicated diverticulitis after launching a protocol at a tertiary hospital.
Cir Esp (Engl Ed)
September 2024
Article Synopsis
- The study evaluates the safety and effectiveness of a new treatment protocol for acute uncomplicated diverticulitis (AUD) that does not utilize antibiotic therapy at a hospital from January 2021 to September 2023.
- Out of 199 patients diagnosed with AUD, 75 were treated as outpatients without antibiotics, and only 7 needed antibiotics later due to complications, but none required surgery.
- The findings support the idea that non-antibiotic treatment can be safe for selected patients, with the presence of bacteriuria identified as a key risk factor for treatment failure.
Article Synopsis
- Recent guidelines suggest outpatient management for acute uncomplicated diverticulitis without antibiotics in selected patients, but adherence to these recommendations varies significantly across national hospitals.
- A survey involving 104 surgeons from 69 hospitals showed that 82.6% of centers offer outpatient management, but only 23.2% have protocols for antibiotic-free treatment, often citing logistical challenges and a lack of evidence.
- There are notable differences between accredited hospitals and others, with accredited centers more likely to implement outpatient care and antibiotic-free protocols, highlighting the need for standardized treatment practices across the board.
Article Synopsis
- The study aimed to identify the ideal patient profiles and outcomes for the fistula laser closure (FiLaC®) technique in treating anal fistulas, focusing on its safety and effectiveness.
- Conducted between October 2015 and December 2021, the study included 36 patients, revealing primary and secondary healing rates of 55.6% and 91.7%, respectively, with no cases of fecal incontinence reported.
- FiLaC® is shown to be a safe and effective option, especially for patients with Crohn's disease, as they had a significantly higher primary healing rate compared to others.
Transanal Hemorrhoidal Dearterialization With Mucopexy Versus Vessel-Sealing Device Hemorrhoidectomy for Grade III to IV Hemorrhoids: Long-term Outcomes From the THDLIGA Randomized Controlled Trial.
Dis Colon Rectum
August 2023
Background: Both transanal hemorrhoidal dearterialization and vessel-sealing device hemorrhoidectomy are safe for grade III to IV hemorrhoid treatment. Whether one of them is superior regarding long-term results remains unclear.
Objective: To compare long-term results after transanal hemorrhoidal dearterialization and vessel-sealing device hemorrhoidectomy.
Short-term Outcomes of Transanal Hemorrhoidal Dearterialization With Mucopexy Versus Vessel-Sealing Device Hemorrhoidectomy for Grade III to IV Hemorrhoids: A Prospective Randomized Multicenter Trial.
Dis Colon Rectum
August 2019
Background: Transanal hemorrhoidal dearterialization with mucopexy and vessel-sealing device hemorrhoidectomy seem to reduce postoperative pain compared with classic excisional hemorrhoidectomy, but whether one of them is superior remains unclear.
Objective: We compared transanal hemorrhoidal dearterialization with mucopexy and vessel-sealing device hemorrhoidectomy.
Design: This was a multicenter, randomized controlled trial.